Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D01KQA
|
|||
| Former ID |
DAP000380
|
|||
| Drug Name |
Nalbuphine
|
|||
| Synonyms |
Intapan; Nalbufina; Nalbuphinum; Intapan (TN); Nalbuphine (INN); Nubain (TN); (5alpha,6alpha)-17-(cyclobutylmethyl)-4,5-epoxymorphinan-3,6,14-triol; 17-cyclobutylmethyl-4,5alpha-epoxymorphinan-3,6alpha,14-triol
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Pain [ICD-11: MG30-MG3Z] | Approved | [1], [2] | |
| Prurigo nodularis [ICD-11: EC91.0; ICD-10: L28.1] | Phase 2/3 | [3] | ||
| Uremic pruritus [ICD-11: EC90.10] | Phase 2/3 | [3] | ||
| Therapeutic Class |
Analgesics
|
|||
| Company |
Endo Pharmaceuticals
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C21H27NO4
|
|||
| Canonical SMILES |
C1CC(C1)CN2CCC34C5C(CCC3(C2CC6=C4C(=C(C=C6)O)O5)O)O
|
|||
| InChI |
1S/C21H27NO4/c23-14-5-4-13-10-16-21(25)7-6-15(24)19-20(21,17(13)18(14)26-19)8-9-22(16)11-12-2-1-3-12/h4-5,12,15-16,19,23-25H,1-3,6-11H2/t15-,16+,19-,20-,21+/m0/s1
|
|||
| InChIKey |
NETZHAKZCGBWSS-CEDHKZHLSA-N
|
|||
| CAS Number |
CAS 20594-83-6
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
9460, 7980064, 11056425, 11466146, 11467266, 11485811, 14828107, 14828108, 39341002, 46507383, 47216707, 47291070, 48110387, 48259160, 48416304, 49698355, 50968490, 56464121, 57359427, 85787879, 92308840, 93166218, 96024934, 103234668, 104000882, 124893623, 126666056, 127291528, 127291529, 127291530, 127291531, 127291532, 127291533, 128691869, 134223042, 134337690, 134993850, 135650680, 137005112, 139813937, 144205561, 164230822, 164763215, 175267073, 176484045, 179116802, 223663773, 223893850, 226395880, 252354412
|
|||
| ChEBI ID |
CHEBI:7454
|
|||
| ADReCS Drug ID | BADD_D01519 | |||
| SuperDrug ATC ID |
N02AF02
|
|||
| SuperDrug CAS ID |
cas=020594836
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Opioid receptor kappa (OPRK1) | Target Info | Modulator | [4] |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | ||||
| Opioid prodynorphin pathway | ||||
| Reactome | Peptide ligand-binding receptors | |||
| G alpha (i) signalling events | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Peptide GPCRs | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1663). | |||
| REF 2 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 070692. | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 4 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.